Sriram Gubbi Mohammad Al-Jundi Jaydira Del Rivero Abhishek Jha Marianne Knue Joy Zou Baris Turkbey Jorge Amilcar Carrasquillo Emily Lin Karel Pacak Joanna Klubo-Gwiezdzinska Frank I-Kai Lin
10.3389/fendo.2020.587065
Front Endocrinol (Lausanne)
2021 Jan 21;11:587065.
dotatate lutathera hypothyroidism paraganglioma peptide receptor radionuclide therapy
CC BY
https://pubmed.ncbi.nlm.nih.gov/33551992/
Hypothyroidism / chemically induced Octreotide / analogs & derivatives Organometallic Compounds / adverse effects Paraganglioma / radiotherapy Radiopharmaceuticals / adverse effects
Hypothyroidism / chemically induced Octreotide / analogs & derivatives Organometallic Compounds / adverse effects Paraganglioma / radiotherapy Radiopharmaceuticals / adverse effects Case Reports Clinical Trial Research Support, N.I.H., Intramural Adult Asymptomatic Diseases Hashimoto Disease / complications Hashimoto Disease / diagnosis Humans Hypothyroidism / diagnostic imaging Hypothyroidism / drug therapy Male Neoplasm Metastasis / radiotherapy Octreotide / adverse effects Octreotide / metabolism Organometallic Compounds / metabolism Paraganglioma / complications Paraganglioma / metabolism Paraganglioma / pathology Positron Emission Tomography Computed Tomography / methods Radiopharmaceuticals / metabolism Succinate Dehydrogenase / metabolism Thyroid Gland / diagnostic imaging Thyroid Gland / metabolism Thyroid Gland / pathology Thyroxine / therapeutic use Treatment Outcome Organometallic Compounds Radiopharmaceuticals gallium Ga 68 dotatate lutetium Lu 177 dotatate SDHB protein, human Succinate Dehydrogenase Thyroxine Octreotide
PMC7859638
33551992
Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
2021